BRIEF-AB Science SA advances SYK kinase inhibitor into full preclinical development

Nov 28 (Reuters) - AB Science SA



* Ultra-Selective SYK Kinase Inhibitor advanced into fullpreclinical development



* Novel small molecule SYK Kinase Inhibitor is named AB8779



* Inhibition of SYK is considered to be good therapeuticstrategy for B-cell malignancies, including non-Hodgkin lymphoma(NHL)



* Inhibition of SYK is considered to be good therapeuticstrategy for chronic lymphocytic leukemia (cll), asthma andrheumatoid arthritisSource text for Eikon: Further company coverage: (Gdynia Newsroom)

via Smart Health Shop Forum http://ift.tt/11BHEtS